ProductSafer
Subscribe
⚠️

Official Product Recall

This notice was issued by U.S. Food & Drug Administration (FDA).

FDA

Fresenius Kabi Issues Nationwide Recall of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials Due to Presence of Glass Particles

FOR IMMEDIATE RELEASE – August 10, 2026 – LAKE ZURICH, Ill.— Fresenius Kabi, an operating company of the Fresenius Group, is recalling one lot of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (20 mg/mL)20 mL vials to the user level. An internal investigation at the firm found the product to cont

This recall was published by U.S. Food & Drug Administration (FDA). View the full official notice for complete details, affected product codes, and what to do next.

View full recall notice

Get an email when another product is recalled

A free Sunday round-up of new UK and US product recalls and safety warnings. Unsubscribe any time.

What should I do?

  • 1.Stop using the product immediately if you have it.
  • 2.Check the full recall notice for affected batch numbers, UPCs, or model numbers.
  • 3.Follow the instructions in the recall notice for returns, replacements, or disposal.
  • 4.If you have health concerns after using the product, contact your GP or call NHS 111.
Back to all recalls

ProductSafer is not affiliated with the FDA. This page reproduces publicly available recall information.

Never miss a finding

Get the latest health findings delivered to your inbox. Only the important stuff. No spam.

We'll send a confirmation email. Unsubscribe anytime.

Recall: Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials